Search results for: Determining Value
Filter search results
NICE’s Social Value Judgments about Equity in Health and Health Care
17 January 2012
…examine the inclusion of social value judgments in NICE guidance decisions and describe the social value judgments about equity in health and health care that NICE has used to guide…
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
5 July 2016
Today EPEMED and The Office of Health Economics (OHE) launch their White Paper “The value of knowing and knowing the value: improving health technology assessment of complementary diagnostics”. This work…
Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
30 May 2017
…HTA methods, in general, do not explicitly account for the value of reducing this public health threat, for example of the “insurance” value of having a treatment available in case…
A New Online Tool for Creating Personal and Social EQ-5D-5L Value Sets
4 May 2018
…blog post describes the method and its potential value. Producing EQ-5D social value sets can be costly and time-consuming. Nancy Devlin and colleagues have been working on a new…
Capturing the Broader Value of Antibiotics
23 November 2023
…that broader value and our report outlines a roadmap to realising its full potential. Key Takeaways Current value assessment of antibiotics cannot address the market failures that hinder antibiotic innovation….
Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?
4 August 2020
…of Health Economics. Available at: https://www.ohe.org/publications/realising-broader-value-vaccines-uk Brassel, S. and Steuten, L., 2020. The Broader Value of Vaccines – The Return on Investment From a Governmental Perspective. OHE Consulting Report, London:…
Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?
1 May 1997
Getting value for money from the use of pharmaceuticals is crucial for the NHS. This publication explores the role for guidelines in generating good quality value for money information examining…
It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
1 December 2021
…out the circumstances in which risk sharing can increase the value of the options available to payers and innovators for mutual benefit when perceptions of value-for-money and of the value…
To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
2 March 2022
…its associated value set. That’s why NICE’s decision not to recommend the EQ-5D-5L value set for England in its new manual is a missed opportunity. Researchers and analysts are left…